YI 111, Inc.
Price Chart
Executive Summary
111, Inc. filed its annual 20-F for FY2025, reporting a 12.8% decline in total net revenue to RMB12.6 billion ($1.8B) driven by a 12.7% drop in B2B product revenue and a 14.5% drop in B2C product revenue, attributed to heightened competition and a strategic shift to an asset-light model via subsidiary divestitures. The company narrowed its net loss slightly to RMB22.5 million ($3.2M) from RMB20.8 million in 2024, while generating positive operating cash flow of RMB119.1 million. A material overhang remains: RMB1.1 billion in redeemable non-controlling interests and accrued liabilities related to 1 Pharmacy Technology's failed STAR Market listing, with RMB282.2 million already repaid and 57.2% of investors agreeing to restructured repayment terms.
Actionable Insight
The top-line decline and persistent net losses signal ongoing competitive and structural headwinds. The RMB1.1B redemption liability from the failed STAR listing is a critical liquidity risk — monitor for further repayment milestones or restructuring agreements. Positive operating cash flow provides a buffer, but the asset-light pivot has yet to stabilize revenue. Watch for Q1 2026 results to see if the divestiture strategy improves margins.
Key Facts
- Total net revenue declined 12.8% YoY to RMB12.6 billion ($1.8B) in FY2025 from RMB14.4 billion in FY2024.
- B2B product revenue fell 12.7% to RMB12.2 billion ($1.7B); B2C product revenue fell 14.5% to RMB223.2 million ($31.9M).
- Net loss was RMB22.5 million ($3.2M) in FY2025, compared to a net loss of RMB20.8 million in FY2024.
- Positive operating cash flow of RMB119.1 million ($17.0M) in FY2025, down from RMB263.0 million in FY2024.
- RMB1.1 billion in redeemable non-controlling interests and accrued liabilities related to 1 Pharmacy Technology's failed STAR Market listing; RMB282.2 million already repaid.
- Cash and cash equivalents stood at RMB511.0 million ($73.1M) as of Dec 31, 2025.
- Company divested three subsidiaries in Q3 2025 as part of an asset-light strategy; these contributed ~20% of 2024 consolidated net revenue.
- Service revenues declined 19.8% to RMB85.4 million ($12.2M) due to lower B2B digital marketing revenue.
Financial Impact
Revenue declined 12.8% YoY; net loss slightly widened to RMB22.5M from RMB20.8M; operating cash flow positive but halved to RMB119.1M.
Risk Factors
- RMB1.1 billion redemption liability from 1 Pharmacy Technology investors could strain liquidity if further repayment demands accelerate.
- Continued revenue contraction from intensified competition and the asset-light transition may delay a return to profitability.
- Regulatory and geopolitical risks from operating in China, including potential PCAOB access issues and CSRC filing requirements for future offerings.
- Dual-class share structure concentrates voting power with founders, limiting minority shareholder influence.
Market Snapshot
Documents Analyzed
This report is based on 13 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001104659-26-052002 |
| Document: yi-20251231xex12d2.htm | 0001104659-26-052002 |
| Document: yi-20251231xex12d1.htm | 0001104659-26-052002 |
| Document: yi-20251231xex8d1.htm | 0001104659-26-052002 |
| Document: yi-20251231xex13d2.htm | 0001104659-26-052002 |
| Document: yi-20251231xex15d3.htm | 0001104659-26-052002 |
| Document: yi-20251231xex13d1.htm | 0001104659-26-052002 |
| Document: yi-20251231xex15d1.htm | 0001104659-26-052002 |
| Document: yi-20251231xex15d4.htm | 0001104659-26-052002 |
| Document: yi-20251231xex15d2.htm | 0001104659-26-052002 |
| Document: 0001104659-26-052002-index-headers.html | 0001104659-26-052002 |
| Document: 0001104659-26-052002-index.html | 0001104659-26-052002 |
| Document: 0001104659-26-052002.txt | 0001104659-26-052002 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
Insider Cluster
| $4.37 awaiting T+1 | awaiting T+1 | — | $4.89 (−11.90%) |
|
Jun 4, 2026
10d ago
|
6-K
| $4.72 $4.78 | ▼ −1.27% | ▼ −3.87% | $4.89 (−3.60%) |
|
May 29, 2026
16d ago
|
Insider Cluster
| $5.28 $5.44 | ▲ +3.03% | ▲ +2.75% | $4.89 (−7.39%) |
|
Apr 30, 2026
6w ago
|
20-F
| $6.20 $6.00 | ▲ +3.23% | ▲ +3.45% | $4.89 (+21.13%) |
|
Apr 9, 2026
9w ago
|
6-K
| $6.41 $6.58 | ▲ +2.65% | ▲ +2.71% | $4.89 (−23.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access